Level C· Early human research exploring benefitsProspective StudyPubMed

Recurrent anal fistulae: limited surgery supported by stem cells.

Garcia-Olmo D., Guadalajara H., Rubio-Perez I., Herreros MD., de-la-Quintana P., Garcia-Arranz M.

Prospective Study on Chronic Wound, Autoimmune Research, published in World J Gastroenterol (2015) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
World J Gastroenterol (2015)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
25805941
PMCID
PMC4363764
DOI
10.3748/wjg.v21.i11.3330
Citations
39

Abstract (original English)

Aim To study the results of stem-cell therapy under a Compassionate-use Program for patients with recurrent anal fistulae. Methods Under controlled circumstances, and approved by European and Spanish laws, a Compassionate-use Program allows the use of stem-cell therapy for patients with very complex anal fistulae. Candidates had previously undergone multiple surgical interventions that had failed to resolve the fistulae, and presented symptomatic recurrence. The intervention consisted of limited surgery (with closure of the internal opening), followed by local implant of stem cells in the fistula-tract wall. Autologous expanded adipose-derived stem cells were the main cell type selected for implant. The first evaluation was performed on the 8(th) postoperative week; outcome was classified as response or partial response. Evaluation one year after the intervention confirmed if complete healing of the fistula was achieved. Results Ten patients (8 male) with highly recurrent and complex fistulae were treated (mean age: 49 years, range: 28-76 years). Seven cases were non-Crohn's fistulae, and three were Crohn's-associated fistulae. Previous surgical attempts ranged from 3 to 12. Two patients presented with preoperative incontinence (Wexner scores of 12 and 13 points). After the intervention, six patients showed clinical response on the 8(th) postoperative week, with a complete cess

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAdultAgedCells, CulturedCompassionate Use TrialsCrohn DiseaseFecal IncontinenceFemaleHumansMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research